Hepatic Lipase as a Focal Point for the Development and Treatment of Coronary Artery Disease
Abstract
Recent epidemiological evidence suggests that although lowering low-density lipoprotein (LDL) cholesterol is important in decreasing cardiovascular disease morbidity and mortality, it accounts only for part of the coronary artery disease (CAD) improvement with lipid-lowering therapy. In the last decade, it has become evident that the atherogenicity of LDL particles is associated not only with their plasma levels, but also with their size and density. The presence of small, dense LDL particles is associated with a three fold increase in CAD risk. Hepatic lipase (HL), a key enzyme in the formation of small, dense LDL particles, modulates their phospholipid and triglyceride contents. The higher the HL activity, the smaller, denser, and more atherogenic the resulting lipoprotein particle. It is, therefore, plausible to hypothesize that at least part of the CAD benefits observed in the recent CAD-prevention pharmacological trials, which are not accounted for by the decrease in LDL-C (LDL-cholesterol), might be explained by a pharmacological effect on LDL size and density, possibly mediated by changes in hepatic lipase activity. By studying patients with dyslipidemia and CAD, we have been able to provide strong evidence that regression of coronary atherosclerosis results from at least two independent effects of lipid-lowering therapy on lipoprotein metabolism: the well known one that leads to changes in LDL-C and apo B levels, and a new pathway of HL-mediated improvement in LDL buoyancy. Finally, HL activity and LDL density appear to be significantly affected by the presence of a common C>T substitution at position -514 with respect to the transcription start site of the HL gene, raising the possibility that the -514 C>T polymorphism may significantly contribute to differences in individual CAD response to lipid-lowering treatment, as seen in the recent major primary and secondary CAD-prevention clinical trials.
Get full access to this article
View all access and purchase options for this article.
References
1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–1276.
2. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128–1131.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823–2828.
4. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289–1298.
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–1307.
6. Downs JR, Clearfield M, Weis S, Whitney E, ShapiroDR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615–1622.
7. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 994;344: 1383–1389.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001–1009.
9. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation 1998; 97:1440–1445.
10. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446–1452.
11. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996;94:2351–2354.
12. Hokanson JE, Austin MA, Brunzell JD. Measurement and clinical significance of low density lipoprotein subclasses. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing Washington, DC: AACC Press; 1997:267–282.
13. Crouse JR, Parks JS, Schey HM, Kahl FR. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res 1985;26:566–574.
14. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917–1921.
15. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner JL, Ordovas JM, Wilson PW, Schaefer EJ. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187–195.
16. Coresh J, Kwiterovich PO Jr, Smith HH, Bachorik PS. Association of plasma triglyceride and LDL particle diameter, density and women. J Lipid Res 1993;34:1687–1697.
17. Gardner CD, Fortmam SP, Krauss RM. Association of small, low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875–881.
18. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882–888.
19. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69–75.
20. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298–306.
21. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb 1993;13:147–153.
22. Brunzell JD, Deeb SS. Lipoprotein lipase, apo CII and hepatic lipase deficiency. In: Scriver CR, Beaudet A, Sly WS, Valle D, Vogelstein B, Childs B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill. In press.
23. Huttunen JK, Enholm C, Kekki M, Nikkila EA. Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridemia: Correlation to sex, age and various parameters of triglyceride metabolism. Clin Sci Mol Med 1976;50:249–260.
24. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD. The visceral adiposity syndrome in Japanese-American men. Obes Res 1994;2:364–371.
25. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000;85:977–982.
26. Carr MC, Hokanson JE, Deeb SS, Purnell JQ, Mitchell ES, Brunzell JD. A hepatic lipase gene promoter polymorphism attenuates the increase in hepatic lipase activity with increasing intra-abdominal fat in women. Arterioscler Thromb Vasc Biol 1999;19:2701–2707.
27. Cohen JC, Vega GL, Grundy SM. Hepatic lipase: New insights from genetic and metabolic studies. Curr Opin Lipidol 1999;10:259–267.
28. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density. Circulation 1999;99:1959–1964.
29. Miller BD, Alderman EL, Haskell WL, Fair JM, Krauss RM. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project. Circulation 1996;94:2146–2153.
30. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B. Independent association between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas’ Atherosclerosis Regression Study (STARS). Metabolism 1993;42:1461–1467.
31. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697–704.
32. Austin MA, King MC, Vranizan KM, Krauss RM. The atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495–506.
33. Cohen JC, Wang Z, Grundy SM, StoeszMR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest 1994;94:2377–2384.
34. Guerra R, Wang J, Grundy SM, Cohen JC. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1997;94:4532–4537.
35. Murtomaki S, Tahvanainen E, Antikainen M, Tiret L, Nicaud V, Jansen H, Ehnholm C. Hepatic lipase gene polymorphism influence plasma HDL levels: Results from Finnish EARS participants. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997;17:1879–1884.
36. Kinnunen PK, Virtanen JA, Vainio P. Lipoprotein lipase and hepatic endothelial lipase: Their roles in plasma lipoprotein metabolism. Atheroscler Rev 1983;11:65–105.
37. Zambon A, Deeb SS, Hokanson JE, Brown BG, Brunzell JD. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998;18:1723–1729.
38. Jansen H, Verhoeven AJ, Weeks L, Kastelein JJ, Halley DJ, van den Ouweland A, Jukema JW, Seidell JC, Birkenhager JC. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered hepatic lipase activity in coronary artery disease patients. Arterioscler Thromb Vasc Biol 1997;17:2837–2842.
39. Tahvanainen E, Syvanne M, Frick MH, Murtomaki-Repo S, Antikainen M, Kesaniemi YA, Kauma H, Pasternak A, TaskinenMR, Ehnholm C. Association of variation in hepatic lipase activity with promoter variation in hepatic lipase gene. The LOCAT Study Investigators. J Clin Invest 1998;101:956–960.
40. Deeb SS, Peng R. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity. J Lipid Res 2000;41:155–158.
41. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996;123:43–56.
42. Anber V, Griffin BA, McConnel M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996;124:261–271.
43. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115–126.
44. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996;37:2473–2491.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published: January 2001
Issue published: January 2001
Keywords
Authors
Metrics and citations
Metrics
Journals metrics
This article was published in Journal of Investigative Medicine.
VIEW ALL JOURNAL METRICSArticle usage*
Total views and downloads: 8
*Article usage tracking started in December 2016
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 0
Crossref: 0
-
Association between Small Dense Low-Density Lipoproteins and High-Dens...
-
The effect of hepatic lipase on coronary artery disease in humans is i...
-
High fat diet induced downregulation of microRNA-467b increased lipopr...
-
Advanced Lipoprotein Testing and Subfractionation Are Clinically Usefu...
-
The Metabolic Syndrome
-
EFFECTS OF ORAL CHONDROITIN SULFATE ON LIPID AND ANTIOXIDANT METABOLIS...
-
Hepatic Lipase Deficiency Delays Atherosclerosis, Myocardial Infarctio...
-
Insulin Resistance, Obesity, Body Fat Distribution, and Risk of Cardio...
-
Sterol-regulatory-element binding protein inhibits upstream stimulator...
-
Endothelial lipase is synthesized by hepatic and aorta endothelial cel...
-
Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus
-
Gender and Ethnic Differences in a Case-Control Study of Dyslipidemia:...
-
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes me...
-
Diagnosis, prevention, and intervention for the metabolic syndrome
-
Hypercholesterolemia and Dyslipidemia: Issues for the clinician
-
Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Typ...
-
The Multicentre Atorvastatin Plaque Stabilisation (MAPS) Study
-
Hepatic lipase
-
Lipases and HDL metabolism
-
Obesity, the metabolic syndrome, and cardiovascular disease
-
Perspectives on Vascular Biology and Diabetes
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
AFMR members can access this journal content using society membership credentials.
AFMR members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
